Search this site

Exec Summary: In vitro diagnostics (IVD) is an emerging HealthTech sub sector that is expected to see significant growth in 2024 and beyond. IVDs are tests performed on samples taken from the body, such as blood, urine, or tissue. They are used to diagnose a wide range of diseases and conditions, including cancer, infectious diseases, and genetic disorders. There are a number of factors driving the growth of the IVD market. One is the increasing prevalence of chronic diseases, such as cancer and diabetes. These diseases require regular monitoring and testing, which is boosting demand for IVDs. Another factor is the growing aging population. Older adults are more likely to suffer from chronic diseases and require more medical care, including IVD testing. The IVD market is also being driven by technological advances. New technologies are making it possible to develop more accurate, sensitive, and rapid IVD tests. For example, next-generation sequencing (NGS) is being used to develop new tests for genetic disorders and cancer. Point-of-care (POC) testing is also becoming increasingly popular. POC tests can be performed outside of a laboratory setting, which makes them more convenient for patients and clinicians. The IVD market is expected to grow at a compound annual growth rate (CAGR) of 6.5% from 2022 to 2028, according to a report by Global Market Insights. This growth will be driven by the factors mentioned above, as well as the increasing demand for personalized medicine. Some of the key trends that are expected to shape the IVD market in 2024 and beyond include: The rise of precision medicine: Precision medicine is an approach to healthcare that takes into account individual variability in genes, environment, and lifestyle. IVDs are playing an increasingly important role in precision medicine by helping clinicians to identify the best treatment for each individual patient. The growth of point-of-care testing: POC testing is becoming more popular because it is convenient and affordable. POC IVDs are expected to play a major role in the early detection and diagnosis of diseases. The increasing use of artificial intelligence (AI): AI is being used to develop new IVD tests and to improve the performance of existing tests. AI is also being used to develop new algorithms for data analysis, which can help clinicians to make better decisions about patient care. Overall, the IVD market is a growing and dynamic sector with a lot of potential. It is a sector to watch in 2024 and beyond. Here are some examples of emerging IVD technologies and companies: Next-generation sequencing (NGS): NGS is a powerful technology that can be used to sequence the entire human genome. NGS is being used to develop new IVD tests for genetic disorders and cancer. For example, the company Illumina has developed a number of NGS-based IVD tests, including the TruSight Oncology 500 test, which is used to identify genetic mutations in cancer patients. Point-of-care (POC) testing: POC testing is becoming increasingly popular because it is convenient and affordable. POC IVDs are expected to play a major role in the early detection and diagnosis of diseases. For example, the company Abbott Laboratories has developed a number of POC IVD tests, including the i-STAT handheld blood analyser, which can be used to test for a variety of blood conditions. Artificial intelligence (AI): AI is being used to develop new IVD tests and to improve the performance of existing tests. AI is also being used to develop new algorithms for data analysis, which can help clinicians to make better decisions about patient care. For example, the company PaigeAI is using AI to develop new IVD tests for cancer. Growth and M&A for Healthcare Technology companies Healthcare Technology Thought Leadership from Nelson Advisors – Market Insights, Analysis & Predictions. Visit https://www.healthcare.digital HealthTech Corporate Development - Buy Side, Sell Side, Growth & Strategy services for Founders, Owners and Investors. Email lloyd@nelsonadvisors.co.uk HealthTech M&A Newsletter from Nelson Advisors - HealthTech, Health IT, Digital Health Insights and Analysis. Subscribe Today! https://lnkd.in/e5hTp_xb HealthTech Corporate Development and M&A - Buy Side, Sell Side, Growth & Strategy services for companies in Europe, Middle East and Africa. Visit www.nelsonadvisors.co.uk #HealthTech #HealthIT #DigitalHealth #lloydgprice #NelsonAdvisors The big question: how will IVD manufacturers meet the growing demand for accurate and rapid testing? The big question in the in vitro diagnostics (IVD) market over the next 12 months is how to meet the growing demand for accurate, sensitive, and rapid testing in a cost-effective way. This is being driven by a number of factors, including: The increasing prevalence of chronic diseases, such as cancer and diabetes The growing aging population The rise of precision medicine The growth of point-of-care (POC) testing IVD manufacturers are responding to this challenge by developing new technologies and products. For example, they are developing NGS-based tests for genetic disorders and cancer, POC tests for early detection and diagnosis of diseases, and AI-powered tools to improve the performance of IVD tests. However, there are still a number of challenges that need to be addressed before IVD testing can be made more widely available and affordable. One challenge is the high cost of some IVD tests. Another challenge is the lack of reimbursement for IVD tests in some countries. In the next 12 months, we can expect to see continued innovation in the IVD market, as manufacturers strive to develop new technologies and products that meet the growing demand for accurate, sensitive, and rapid testing in a cost-effective way. We can also expect to see governments and healthcare insurers take steps to improve reimbursement for IVD tests, in order to make them more accessible to patients. Potential acquirers in 2024 The following companies are likely to be involved in M&A activity in the in vitro diagnostics (IVD) market in 2024: Large IVD companies: These companies have a strong financial position and are looking to expand their product portfolios and geographic reach. Examples include: Abbott Diagnostics Becton, Dickinson and Company (BD) Danaher Corporation Hologic, Inc. Johnson & Johnson QIAGEN N.V. Roche Diagnostics Siemens Healthineers Thermo Fisher Scientific Inc. Small and medium-sized IVD companies: These companies have innovative technologies and products that are attractive to larger IVD companies. Examples include: Bio-Rad Laboratories, Inc. CoaguSense Illumina, Inc. Myriad Genetics, Inc. NanoString Technologies, Inc. PaigeAI QuidelOrtho Companies outside of the IVD industry: These companies may be interested in acquiring IVD companies in order to expand their product portfolios or to gain access to new technologies. Examples include: Alphabet Inc. (Google) Amazon.com, Inc. Apple Inc. Microsoft Corporation In addition to these companies, there are a number of private equity firms that are also interested in investing in the IVD market. These firms can provide capital to help IVD companies grow and expand. Key M&A trends predicted in the in vitro diagnostics market in 2024 Here are some key M&A trends predicted in the in vitro diagnostics (IVD) market in 2024: Large IVD companies acquiring smaller IVD companies: This trend is likely to continue, as large IVD companies look to expand their product portfolios and geographic reach. For example, in 2022, Danaher Corporation acquired Cytiva for $25.4 billion. Cytiva is a leading provider of life sciences research and manufacturing tools. This acquisition gives Danaher a strong presence in the IVD market, as Cytiva offers a wide range of IVD products, including immunoassays, molecular diagnostics, and POC testing solutions. Companies outside of the IVD industry acquiring IVD companies: This trend is also likely to continue, as companies outside of the IVD industry look to expand their product portfolios or to gain access to new technologies. For example, in 2022, Alphabet Inc. (Google) acquired Fitbit for $2.1 billion. Fitbit is a leading provider of wearable fitness devices. This acquisition gives Alphabet access to Fitbit's health data, which could be used to develop new IVD products and services. Private equity firms investing in IVD companies: Private equity firms are also likely to continue investing in the IVD market. This is because the IVD market is a growing market with a lot of potential. For example, in 2022, Hellman & Friedman acquired Bio-Rad Laboratories for $8.2 billion. Bio-Rad is a leading provider of life science research and clinical diagnostic products. This acquisition gives Hellman & Friedman a strong presence in the IVD market. In addition to these trends, we can also expect to see M&A activity in the IVD market driven by the following factors: The rise of precision medicine: Precision medicine is an approach to healthcare that takes into account individual variability in genes, environment, and lifestyle. IVDs are playing an increasingly important role in precision medicine by helping clinicians to identify the best treatment for each individual patient. This is driving demand for IVD products and services, and making the IVD market more attractive to potential acquirers. The growth of point-of-care (POC) testing: POC testing is becoming more popular because it is convenient and affordable. POC IVDs are expected to play a major role in the early detection and diagnosis of diseases. This is driving demand for POC IVD products and services, and making the POC IVD market more attractive to potential acquirers. The increasing use of artificial intelligence (AI): AI is being used to develop new IVD tests and to improve the performance of existing tests. AI is also being used to develop new algorithms for data analysis, which can help clinicians to make better decisions about patient care. This is driving demand for AI-powered IVD products and services, and making the AI-powered IVD market more attractive to potential acquirers. Overall, we can expect to see a significant amount of M&A activity in the IVD market in 2024. This activity will be driven by the factors mentioned above, as well as the increasing importance of IVD testing in healthcare. Final Thoughts: The future of the in vitro diagnostics (IVD) market is bright. The market is expected to grow at a compound annual growth rate (CAGR) of 6.5% from 2022 to 2028, according to a report by Global Market Insights. This growth will be driven by a number of factors, including: The increasing prevalence of chronic diseases, such as cancer and diabetes The growing aging population The rise of precision medicine The growth of point-of-care (POC) testing The increasing use of artificial intelligence (AI) Here are some specific trends that are expected to shape the future of the IVD market: The rise of precision medicine: Precision medicine is an approach to healthcare that takes into account individual variability in genes, environment, and lifestyle. IVDs are playing an increasingly important role in precision medicine by helping clinicians to identify the best treatment for each individual patient. The growth of point-of-care (POC) testing: POC testing is becoming more popular because it is convenient and affordable. POC IVDs are expected to play a major role in the early detection and diagnosis of diseases. The increasing use of artificial intelligence (AI): AI is being used to develop new IVD tests and to improve the performance of existing tests. AI is also being used to develop new algorithms for data analysis, which can help clinicians to make better decisions about patient care. In addition to these trends, the future of the IVD market will also be shaped by the following factors: The increasing demand for personalised medicine: Personalised medicine is an approach to healthcare that tailors treatments to the individual patient's needs. IVDs are playing an increasingly important role in personalised medicine by helping clinicians to identify the best treatment for each individual patient. The growing importance of preventive care: Preventive care is the practice of preventing diseases from occurring in the first place. IVDs are playing an increasingly important role in preventive care by helping clinicians to identify early signs of disease. The increasing demand for affordable healthcare: Healthcare costs are rising around the world. IVDs can help to reduce healthcare costs by making it possible to diagnose and treat diseases more efficiently. Overall, the future of the IVD market is very promising. The market is expected to grow significantly in the coming years, driven by a number of factors, including the increasing prevalence of chronic diseases, the growing aging population, the rise of precision medicine, the growth of point-of-care testing, and the increasing use of artificial intelligence. Growth and M&A for Healthcare Technology companies Healthcare Technology Thought Leadership from Nelson Advisors – Market Insights, Analysis & Predictions. Visit https://www.healthcare.digital HealthTech Corporate Development - Buy Side, Sell Side, Growth & Strategy services for Founders, Owners and Investors. Email lloyd@nelsonadvisors.co.uk HealthTech M&A Newsletter from Nelson Advisors - HealthTech, Health IT, Digital Health Insights and Analysis. Subscribe Today! https://lnkd.in/e5hTp_xb HealthTech Corporate Development and M&A - Buy Side, Sell Side, Growth & Strategy services for companies in Europe, Middle East and Africa. Visit www.nelsonadvisors.co.uk #HealthTech #HealthIT #DigitalHealth #lloydgprice #NelsonAdvisors

Exec Summary Overall, 2023 presented a mixed picture for HealthTech M&A. While the sector retained significant investor interest and exhibited promising growth in certain areas, the broader economic context impacted valuations and slowed down the pace of deals. The average multiples in HealthTech M&A declined in 2023 compared to 2022. Here's a quick recap of the key points: Overall decrease: EV/Sales: Down from 5.6x in 2022 to 4.5x in 2023 (a decrease of 20%) EV/EBITDA: Down from 12.5x in 2022 to 11.0x in 2023 (a decrease of 12%) Averages by sub-sector: Telehealth: 5.5x Wellness: 4.0x Drug discovery: 7.0x Medical devices: 5.0x Healthcare IT: 3.5x Whether 2023 was a good or bad year for HealthTech M&A depends on your perspective and what criteria you prioritise. Here's a balanced view: Positives: Continued activity: Despite the decline in multiples compared to 2022, the HealthTech M&A market remained active in 2023. This suggests that investors still see significant potential in the sector and are willing to invest, even with a more cautious approach. Consolidation opportunities: The decline in valuations could create opportunities for strategic acquisitions and mergers, enabling companies to expand their reach and market share. Focus on fundamentals: The increased scrutiny on profitability and long-term prospects could lead to a more sustainable and healthy M&A market in the long run. Negatives: Lower valuations: The decline in multiples means that companies are fetching lower prices than they might have in previous years. This could impact the ability of some startups to raise capital and scale their businesses. Investor uncertainty: Macroeconomic factors like inflation and interest rate hikes continue to create uncertainty, which could dampen investor appetite for M&A in the near future. Slower deal pace: Compared to the record-breaking pace of 2022, the number of M&A deals might have decreased in 2023, reflecting the cautiousness of investors. Corporate Development for Healthcare Technology companies in EMEA Healthcare Technology Thought Leadership from Nelson Advisors – Market Insights, Analysis & Predictions. Visit https://www.healthcare.digital HealthTech Corporate Development - Buy Side, Sell Side, Growth & Strategy services for Founders, Owners and Investors. Email lloyd@nelsonadvisors.co.uk HealthTech M&A Newsletter from Nelson Advisors - HealthTech, Health IT, Digital Health Insights and Analysis. Subscribe Today! https://lnkd.in/e5hTp_xb HealthTech Corporate Development and M&A - Buy Side, Sell Side, Growth & Strategy services for companies in Europe, Middle East and Africa. Visit www.nelsonadvisors.co.uk HealthTech M&A transactions HealthTech M&A transactions can vary significantly in terms of size, nature, and market conditions. The multiples, or valuation metrics, used in these transactions are typically based on factors such as revenue, earnings, or users/subscribers, and can differ based on the company's stage of development, growth prospects, market position, and other relevant factors. Revenue Multiples: One commonly used metric is the revenue multiple, which measures the value of a company relative to its revenue. In HealthTech, revenue multiples can range widely depending on factors such as the company's growth rate, profitability, and competitive landscape. In the past, revenue multiples for HealthTech companies have ranged from 1x to 10x or more, with some highly valued companies commanding even higher multiples. Earnings Multiples: Another metric used in M&A transactions is the earnings multiple, which compares a company's valuation to its earnings (e.g., EBITDA - Earnings Before Interest, Taxes, Depreciation, and Amortization). Earnings multiples for HealthTech companies can vary based on factors such as profitability, growth potential, and industry trends. The range of earnings multiples in the HealthTech sector has historically been broad, spanning from single-digit multiples to higher double-digit or triple-digit multiples for high-growth, high-margin companies. User/Subscriber Multiples: In some cases, HealthTech companies with user-focused business models, such as telemedicine or digital health platforms, may be valued based on the number of users or subscribers they have acquired. Valuations based on these metrics can vary significantly depending on the size of the user base, user engagement, revenue per user, and other factors. While there isn't a fixed average multiple for user/subscriber-based valuations in HealthTech M&A, they can range from a few dollars per user to several hundred or even thousands of dollars per user, depending on the company's unique circumstances. Key trends driving strategic healthtech acquisitions: Here are some of the specific trends that are driving strategic healthtech acquisitions in today's market: The increasing demand for digital health solutions: The aging population and the growing prevalence of chronic diseases are driving the demand for digital health solutions. This is creating opportunities for healthtech companies that offer products and services that can improve the quality of care and reduce costs. The rise of artificial intelligence and machine learning: Artificial intelligence and machine learning are rapidly transforming the healthcare industry. These technologies are being used to develop new diagnostic tools, improve the efficiency of clinical workflows, and personalize treatment plans. The growing focus on preventive care: The healthcare industry is shifting its focus from reactive care to preventive care. This is creating opportunities for healthtech companies that offer products and services that can help people stay healthy. The increasing regulatory scrutiny: The healthcare industry is heavily regulated. This can make it difficult for healthtech companies to bring new products and services to market. However, it also creates opportunities for companies that can help healthcare organizations comply with regulations. Overall, the strategic healthtech acquisition market is very active. There are a number of factors driving this activity, including the increasing demand for digital health solutions, the rise of artificial intelligence and machine learning, the growing focus on preventive care, and the increasing regulatory scrutiny. Key priorities for strategic healthtech acquirers: The key priorities for strategic HealthTech acquirers are: Growth: Strategic acquirers are looking for companies that can help them grow their businesses. This could mean acquiring companies that operate in new markets, offer new products or services, or have a strong customer base. Innovation: Strategic acquirers are also looking for companies that are innovative and can help them stay ahead of the competition. This could mean acquiring companies that are developing new technologies or have a strong track record of innovation. Market share: Strategic acquirers may also be looking to acquire companies that will give them a larger market share. This could be in a specific market or in the overall healthtech market. Competitive advantage: Strategic acquirers may also be looking to acquire companies that will give them a competitive advantage. This could be through access to new technologies, markets, or customers. Revenue: Strategic acquirers may also be looking to acquire companies that will generate additional revenue. This could be through the sale of products or services, or through the expansion of the acquirer's existing business. Profitability: Strategic acquirers may also be looking to acquire companies that are profitable. This could mean acquiring companies that have a strong track record of profitability or that have the potential to become profitable in the future. Exit strategy: Strategic acquirers may also have an exit strategy in mind, such as taking the acquired company public or selling it to another company. This will affect the type of company they are looking to acquire and the price they are willing to pay. The Future of HealthTech M&A The future of HealthTech M&A is likely to be shaped by several key trends: Rising Healthcare Costs and Pressure on Payers: Healthcare costs are rising at an alarming rate, putting pressure on payers, such as insurance companies and government programs. This is driving a demand for M&A activity that can help to improve efficiency and reduce costs. Technological Innovation: The healthcare industry is undergoing a period of rapid technological innovation, with the emergence of new technologies such as artificial intelligence, robotics, and genomics. This is creating opportunities for M&A activity that can help companies to acquire new technologies and capabilities. Changing Consumer Expectations: Consumers are becoming more informed and demanding about their healthcare experiences. They are increasingly looking for personalized, convenient, and affordable care. This is driving a demand for M&A activity that can help companies to meet these evolving consumer expectations. Global Expansion: The healthcare industry is becoming increasingly globalized, with companies expanding into new markets to reach a wider patient base. This is creating opportunities for M&A activity that can help companies to enter new markets and gain access to new technologies and talent. Regulatory Landscape: The regulatory landscape for healthcare M&A is complex and constantly evolving. Companies need to carefully consider the regulatory implications of any acquisition before proceeding. Here are some specific examples of how these trends are likely to shape the future of HealthTech M&A: We will see more deals between payers and providers: Payers are looking to acquire providers to gain more control over the healthcare system and improve their ability to manage costs. Providers are looking to acquire payers to gain access to new patient populations and improve their financial stability. We will see more deals between technology companies and healthcare companies: Technology companies are looking to acquire healthcare companies to gain access to new markets and new data sources. Healthcare companies are looking to acquire technology companies to improve their ability to collect, analyse, and use data to improve patient care. We will see more deals between healthcare companies and consumer-facing companies: Healthcare companies are looking to acquire consumer-facing companies to improve their ability to reach and engage with patients. Consumer-facing companies are looking to acquire healthcare companies to gain access to new data and insights into the healthcare industry. Overall, the future of HealthTech M&A is bright. The industry is undergoing a period of rapid change and innovation, and M&A is playing a key role in driving this transformation. As these trends continue to develop, we can expect to see even more M&A activity in the healthcare sector in the years to come. Corporate Development for Healthcare Technology companies in EMEA Healthcare Technology Thought Leadership from Nelson Advisors – Market Insights, Analysis & Predictions. Visit https://www.healthcare.digital HealthTech Corporate Development - Buy Side, Sell Side, Growth & Strategy services for Founders, Owners and Investors. Email lloyd@nelsonadvisors.co.uk HealthTech M&A Newsletter from Nelson Advisors - HealthTech, Health IT, Digital Health Insights and Analysis. Subscribe Today! https://lnkd.in/e5hTp_xb HealthTech Corporate Development and M&A - Buy Side, Sell Side, Growth & Strategy services for companies in Europe, Middle East and Africa. Visit www.nelsonadvisors.co.uk

Exec Summary: Teladoc’s long-time CEO left the company this week after its share price hit an 8-year low. Amwell's (AMWL) share price has collapsed from a $35 share price 3 years ago down to a $1 share price today.Amwell's $6 Billion market cap peaked in 2021 and has since declined over 96% down to a $235 million market cap today resulting in the possibility of being delisted from NYSE. What's going on? Why has confidence in generalist TeleHealth companies collapsed on the public markets? Market correction: The Telehealth sector may have been overvalued at its peak, and a correction was inevitable. This could be due to a number of factors, such as investor enthusiasm outpacing the actual profitability of these companies, or a realisation that the long-term potential of the Telehealth market was not as large as initially thought. Regulation: The regulatory environment for Telehealth is still evolving, and there is some uncertainty about how future regulations will impact the industry. This uncertainty could be making investors cautious. Competition: The Telehealth market is becoming increasingly competitive, which could be putting pressure on margins for Telehealth companies. Burnout and churn: There is a concern that the initial wave of demand for Telehealth services may have been driven by the COVID-19 pandemic, and that demand could now start to decline. This could lead to problems with customer churn for Telehealth companies. Maturity of the market: The Telehealth market is still relatively young, and it may take some time for companies to develop proven business models. Investors may be impatient with companies that are not yet profitable. It's important to note that TeleHealth still holds promise for the future. The convenience and accessibility it offers are undeniable. However, the industry needs to address these challenges to regain investor confidence and ensure long-term success. Growth and M&A for Healthcare Technology companies Healthcare Technology Thought Leadership from Nelson Advisors – Market Insights, Analysis & Predictions. Visit https://www.healthcare.digital HealthTech Corporate Development - Buy Side, Sell Side, Growth & Strategy services for Founders, Owners and Investors. Email lloyd@nelsonadvisors.co.uk HealthTech M&A Newsletter from Nelson Advisors - HealthTech, Health IT, Digital Health Insights and Analysis. Subscribe Today! https://lnkd.in/e5hTp_xb HealthTech Corporate Development and M&A - Buy Side, Sell Side, Growth & Strategy services for companies in Europe, Middle East and Africa. Visit www.nelsonadvisors.co.uk #HealthTech #HealthIT #DigitalHealth #lloydgprice #NelsonAdvisors Generalists vs. Specialists: TeleHealth Providers The key differences between generalist and specialist TeleHealth companies can be identified as follows: Broader Scope, Thinner Expertise: Generalist TeleHealth companies cater to a wide range of health concerns. While convenient, this might not provide the in-depth care needed for complex conditions. Patients might prefer specialists with a deeper understanding of their specific needs. Limited Diagnostics and Procedures: General TeleHealth consultations often lack the ability to perform thorough physical examinations or complex procedures. This can be a limitation for many health issues. Specialists might have access to more advanced diagnostics or be able to perform procedures remotely for specific conditions. Challenges for Generalists: Building Trust: Establishing trust with patients remotely can be more challenging for generalists who haven't built a pre-existing patient relationship. Specialists, often seen in-person beforehand, might have an advantage here. Focus on Simple Issues: General TeleHealth consultations might be well-suited for addressing common, non-urgent concerns. However, for complex or chronic conditions, specialists with a tailored approach might be preferred. The Rise of TeleHealth Specialists: Fulfilling a Niche: TeleHealth specialists are emerging to address specific areas like dermatology, mental health, or cardiology. This allows for more focused consultations, potentially leading to better patient outcomes. Leveraging Technology: Specialists are increasingly utilising specialised telemedicine platforms that incorporate relevant diagnostic tools or remote monitoring capabilities for their field. Amwell Investor confidence in Amwell has taken a hit in the past year. Here are some reasons specific to Amwell that might be contributing to the decline: Missed Earnings Expectations: Amwell may have fallen short of analyst expectations for revenue or profitability in recent quarters. This disappoints investors who were hoping for strong growth. Lower-than-anticipated User Growth: Compared to initial forecasts, Amwell might not be adding new users at the expected pace. This could indicate a slowdown in Telehealth adoption or limitations in Amwell's user acquisition strategy. Increased Costs: Amwell might be facing rising costs for technology, marketing, or acquiring new clients. This could squeeze profit margins and make the company less attractive to investors. Focus on Lower-acuity Visits: Amwell might be primarily facilitating consultations for less serious medical issues. While this is a large market segment, investors might be looking for companies with a focus on more complex and profitable consultations. Acquisitions not panning out: Amwell's past acquisitions might not be delivering the expected value or synergies, leading to investor disappointment. Teladoc Similar to Amwell, Teladoc's investor confidence has also taken a beating in the past year. Here's a breakdown of some potential reasons specific to Teladoc: Missed Earnings Expectations: Like Amwell, Teladoc might have underperformed analyst expectations for revenue or profitability in recent quarters. This disappoints investors who were hoping for strong growth. Lower-than-anticipated Member Growth: Teladoc might not be adding new members (patients or healthcare providers) at the expected pace. This could indicate a slowdown in Telehealth adoption or limitations in Teladoc's user acquisition strategy. Integration Challenges: Teladoc made significant acquisitions in recent years (e.g., Livongo). Integrating these companies effectively can be complex and expensive. Delays or difficulties in this process can erode investor confidence. Increased Costs: Just like Amwell, Teladoc might be facing rising costs for technology, marketing, or integrating acquisitions. This could squeeze profit margins and make the company less attractive to investors. On top of these Teladoc specific factors, the broader Telehealth market struggles also likely play a role: Market Correction: Teladoc's stock price might have been inflated during the initial COVID-19 surge. As the market adjusts to a post-pandemic landscape, investors are more focused on long-term profitability. Increased Competition: The Telehealth market is getting more crowded, putting pressure on Teladoc's market share and pricing power. Burnout and Churn: Concerns exist that the initial boom in demand for Teladoc's services was temporary, potentially leading to user churn and impacting the company's subscriber base. Maturity of Telehealth Business Model: Teladoc might still be refining its business model to achieve sustainable profitability, disappointing investors seeking immediate results. The Future of TeleHealth: While general TeleHealth might need to adapt, the overall industry still holds promise. Here's what could happen: Hybrid Model: A blend of general TeleHealth consultations for initial assessments, followed by referrals to specialists for ongoing care, could be a successful approach. Technology Advancements: Development of more advanced remote diagnostics and procedures could expand the capabilities of general TeleHealth in the future. Overall, the focus is shifting towards TeleHealth that offers a more specialized and tailored approach to patient care. This doesn't negate the role of generalists, but emphasises the value of specialists in specific areas. Growth and M&A for Healthcare Technology companies Healthcare Technology Thought Leadership from Nelson Advisors – Market Insights, Analysis & Predictions. Visit https://www.healthcare.digital HealthTech Corporate Development - Buy Side, Sell Side, Growth & Strategy services for Founders, Owners and Investors. Email lloyd@nelsonadvisors.co.uk HealthTech M&A Newsletter from Nelson Advisors - HealthTech, Health IT, Digital Health Insights and Analysis. Subscribe Today! https://lnkd.in/e5hTp_xb HealthTech Corporate Development and M&A - Buy Side, Sell Side, Growth & Strategy services for companies in Europe, Middle East and Africa. Visit www.nelsonadvisors.co.uk #HealthTech #HealthIT #DigitalHealth #lloydgprice #NelsonAdvisors

NeuroLaunch NeuroLaunch is the world’s first accelerator program for neuroscience startups. We apply the methodology of lean early-stage company acceleration, which has risen to global prominence as a model for high-tech startups, to neuroscience. We provide a new pathway to success for neuroscience startups: • Seed funding • Specialized 90-day curriculum • Strategic partnerships • World-class mentor network • Direct introductions to neuro-oriented VCs and angel investors We welcome prospective Mentors, Partners, Sponsors, Investors, and NeuroLaunch Companies. To learn more, visit www.NeuroLaunch.com Why is NeuroLaunch important? Humanity is in the early stages of a worldwide neuroscience renaissance. Recent public initiatives, such as the White House BRAIN Initiative and the EU’s Human Brain Project, have resulted in expanded funding for brain and nervous system research. However, commercialization of neuroscience to solve real-world problems has long been inefficient and serendipity-driven. This process delays the availability of novel therapies and products. It results in abandoned intellectual property and often leads to most value being captured by large corporations, instead of by early-stage innovators themselves. NeuroLaunch solves these problems by conveying the startup accelerator culture to neuroscience, helping innovators rapidly bring technologies to market so they can help society. Who can become a NeuroLaunch company? In our community, we share a common language of neuro-innovation. Any “neuro-startup”—defined broadly as a venture whose main endeavor involves neuroscience, be it a device, drug, software, or consumer business—qualifies to apply as a NeuroLaunch Company. How do I get involved in NeuroLaunch? We welcome prospective Mentors, Partners, Sponsors, Investors, and NeuroLaunch Companies. To learn more, visit www.NeuroLaunch.com or contact info@neurolaunch.com Israel Brain Technologies’ (IBT) Brainnovations and NeuroLaunch The two pre-eminent accelerator programs for brain technology startups, Israel Brain Technologies’ (IBT) Brainnovations and NeuroLaunch, announced a historic global partnership for fostering investment, innovation, and international dialogue between U.S. and Israeli entrepreneurs working in the fields of neuroscience and neurotechnology. NeuroLaunch, headquartered in Atlanta and founded in 2014, is supported by over 150 expert mentors worldwide and has funded two batches of startups to date, with 11 companies receiving investment and over 60 companies presenting at its Demo Day events. Brainnovations was launched by Tel Aviv-based Israel Brain Technologies in 2015 and has held two successful batches to date with 16 companies, which to date have raised $7M. Both organizations are planning on accepting their next batch of companies for the summer of 2017. The IBT-NeuroLaunch partnership kicked off today with an on-stage announcement and joint working sessions at the Israel Brain Technologies’ BrainTech Conference March 6-7, 2017 in Tel Aviv. “We are entering a golden age of brain technology that will forever transform human health and happiness. The global partnership between Israel Brain Technologies and NeuroLaunch, as the first of its kind, will foster international collaboration among brain tech entrepreneurs in order to accelerate their success,” said Dr. Jordan Amadio, NeuroLaunch Co-Founder and Managing Partner. “Increasing collaboration between American and Israeli brain technology entrepreneurs will help benefit humanity with extraordinary opportunities. This partnership will combine the most outstanding elements of both communities in order to spur new growth for neuroscience and neurotech companies,” said Miri Polachek, Executive Director of Israel Brain Technologies. In the summer of 2017, the two organizations will partner to support companies participating in both accelerator programs. The entrepreneurs going through the two programs will interact and share resources, including partners, mentors, content, market access, and funding opportunities. This will mark the first international collaboration specifically geared toward maximising success for brain technology startups via global partnerships. Prior IBT Brainnovations portfolio companies include: A mobile eye-tracking application for early detection of cognitive decline. A directional deep brain stimulation device for the treatment of epilepsy and other brain disorders. Genetic and environmental based platform to tailor medications for psychiatric disorders. A machine learning based system for improving quality and speed of medical image diagnosis , focusing on head and neck scans. A next generation brain stimulation device for the treatment of ADHD. A brain computer interface-based authentication technology for the healthcare industry. Prior NeuroLaunch portfolio companies include: A neuro-wearable device platform for tracking and gamification of human infant brain development. A next-generation neuro-endovascular device employing novel technology to improve patient outcomes after acute ischemic stroke. An algorithmic platform enabling personalized genomics to treat epilepsy and other disorders. The future of cloud-based, three-dimensional neuroimaging for research and neurosurgical planning. A comprehensive system for radically streamlining clinical trials recruitment for neuro and other markets. Mobile-friendly peripherals for vital signs monitoring and neuroscience-based gamification of prevention strategies for stroke and other diseases. Long term goals for the U.S.-Israeli partnership include sharing mentors and resources for portfolio companies, co-developing an international network of programs for brain technology startups, and launching a U.S.-Israeli exchange for neuroscience entrepreneurs. This will enable access to global markets and collaborations for both U.S. and Israeli neuroscience companies and facilitate new synergies. Beginning in July 2017, NeuroLaunch and IBT will collaborate on joint events, including conferences for connecting startups with investors, and facilitate sharing of content across their two accelerators. IBT and NeuroLaunch are also spearheading a long-term strategic plan for joint funding and investing efforts, which is expected to foster a larger number of brain-related technology companies across both the U.S. and Israel. Source : http://israelbrain.org/global-u-s-israeli-partnership-for-brain-technology-startup-companies-announced/ http://neurolaunch.com/?q=portfolio Growth and M&A for Healthcare Technology companies Healthcare Technology Thought Leadership from Nelson Advisors – Market Insights, Analysis & Predictions. Visit https://www.healthcare.digital HealthTech Corporate Development - Buy Side, Sell Side, Growth & Strategy services for Founders, Owners and Investors. Email lloyd@nelsonadvisors.co.uk HealthTech M&A Newsletter from Nelson Advisors - HealthTech, Health IT, Digital Health Insights and Analysis. Subscribe Today! https://lnkd.in/e5hTp_xb HealthTech Corporate Development and M&A - Buy Side, Sell Side, Growth & Strategy services for companies in Europe, Middle East and Africa. Visit www.nelsonadvisors.co.uk #HealthTech #HealthIT #DigitalHealth #lloydgprice #NelsonAdvisors

Almost all of the technology incorporated into Google Glass, (Wi-Fi, Bluetooth, cameras, voice activation etc.) is already available on smartphones today. The key difference will be how we interact with this technology when these features are available in our peripheral vision. Besides from the entertainment value of Google Glass, several early adopters have been trialing the Google Glass Explorer edition to research the benefits the product may hold for medical professionals and patients. Read on to discover the top 7 ways Google Glass is revolutionising healthcare. 1. Data Access What could be simpler than walking into a hospital room to find that important, up to date data about the patient inside is automatically displayed in the corner of your eye? This is the Google Glass vision. The most highly publicised use of Google Glass in healthcare so far has involved surgical procedures. Phillips and Accenture Technology lab have teamed up to help surgeons view patients’ vital statistics, such as heart rate, oxygen levels and blood pressure on the Google Glass display. This hands free, voice activated system eliminates the need during surgical procedures to turn around to check a computer monitor. Pristine is a tech start-up at the forefront of developing Glass apps for surgeons, nurses and anesthesiologists for use before, during and after surgery. Kyle Samani, the CEO of Pristine says “If you’re running around all day, using your hands, and you need to access and share information, Glass is going to change how you do your job.” Kyle Samani, CEO of Pristine But the ability to access patient data from an EHR (electronic health record) is useful for any healthcare professional, not just surgeons who need to sustain a high level of concentration. Some have argued that maintaining eye contact with patients, rather than turning to a computer to look up information, will help develop stronger relationships. A translation service may also help improve communication between healthcare professionals and foreign patients. 2. Hands-free equals clean hands Critically, wearable technology such as Glass reduces the need for healthcare professionals to touch devices before or after dealing with a patient. Studies have shown that keyboards, smart phones and other electronic devices used on a regular basis are usually teeming with harmful bacteria. Chances are your iPhone is filthier than the average public toilet seat. With thousands of patients falling ill each year through viruses picked up in hospitals, it is vital that each healthcare professional keeps their hands as clean as possible. Google Glass might also work with Microsoft Kinect technology, which will allow surgeons and other healthcare professionals to select and modify data on a screen with movement sensors, i.e. just by waving a hand in front of the monitor. 3. Emergency Situations This is an area with massive potential. The Glass platform allows users to view and live stream video recordings in a way that has never been simpler. Consider these situations: A Google Glass user in the street may happen to record a car accident; the user can then contact Emergency Services and live stream the incident as it unfolds. A woman at home finds her husband has collapsed and is not breathing. She calls an ambulance and in the meantime follows instructions for performing chest compressions. She does this with the help of a first aid video from NHS Choices displayed on Google Glass. A visiting nurse, social worker or paramedic who does not have the same expertise as hospital specialists can live stream a video of the patient and receive help and guidance in assessing the situation. A surgeon stumbles upon a tricky situation mid-procedure and requires immediate assistance from a fellow surgeon in a different hospital, perhaps on the other side of the world. 4. Educational Resource Trauma surgeon, FutureMed graduate and early adopter of Google Glass, Dr. Rafael Grossmann, believes that Glass could revolutionize the healthcare industry in a number of ways relating to teaching and consultation. “This device and its platform, are certainly intuitive tools that have a great potential in Healthcare, and specifically for surgery, could allow better intra-operative consultations, surgical mentoring and potentiate remote medical education, in a very simple way.” By live streaming an operation to Google Hang Out as Grossman has done, students can have a much better insight into the challenges involved during each procedure and may feel more prepared for the next stage of development in the medical profession. On the issue of privacy, Grossman explains how he was able to work around this issue by obtaining proper consent before the operation, and ensuring that no personal information was revealed during the recording. 5. Reducing Errors A simple human error, a momentary lapse of concentration on the part of a healthcare could have tragic results. Doctors and nurses are often tired and overworked, which is why disruptive technology to instill safeguards could save lives. Alerts and reminders will be displayed in Google Glass for health workers with hectic schedules. When administering prescription pills, a pharmacist or nurse in a hospital or care home Google Glass will automatically scan the barcode for medication and compare this with the patient health record in front of them. Instructions for recommended dosage will also be displayed. A Google Glass app could instantly alert the health worker if any mistakes have been made. Pristine Checklists Pristine is also developing safety checklists that can be used in different locations across a hospital. “Pristine CheckLists are the simplest and safest way to implement checklists in any clinical environment. Because they’re on Google Glass, they’re hands-free and voice-driven. They’re uniquely suited for patient care environments and easy to use. Perhaps best of all, Pristine can teach you how to use Pristine CheckLists in just minutes.” These checklists may be used for ‘instrument cleaning, drug preparation, complicated tests and procedures etc.’ 6. Anyone, anywhere, at any time This is a somewhat controversial positive point for Google Glass as many people have serious privacy concerns relating to their care. Glass itself is not particularly secure, since anyone could pick up the glasses and access confidential information. Nevertheless, it cannot be denied that continuous documentation of events has obvious benefits in a healthcare setting. For example, a physiotherapist might play past videos of a patient’s movement to evaluate their progress over time. Health workers may take more care to follow correct protocols such as washing their hands properly and pay more attention to their interpersonal skills when dealing with patients. Similarly, patients with the headwear may record their interactions with GPs and use this later to recall the doctor’s instructions, or when forging a complaint against the practitioner. 7. Just for Patients Just like smartphones have basic functions and additional apps, Google Glass has ‘Glassware’. Glass wearers may display a Yoga class video for example, helpful when performing a ‘downward dog’ or other stretches that requires the user to take their eyes off a screen. Glass wearers may also want to scan barcodes in supermarkets to help with meal planning. As health and fitness self-tracking apps are already some of the most popular on the market today, it’s likely that Glassware will change the way we approach our health and fitness once again. ‘Leading provider of Fitness equipment’ Fitstream, show what a fitness Glassware app will look like while wearing the glasses. Glassware could have enormous benefits for disabled users. Google Glass could tell a partially sighted user if they are holding a can of soup or a can of beans, perhaps even read the contents of a letter. Deaf users may eventually have a running commentary displayed on Google Glass. Autistic users might be given information on what emotions people are displaying by Glass analyzing their facial expressions. The hands free capabilities have obvious benefits for users with mobility issues. Glass has already been piloted by disabled users such as Alex Blaszczuk, who is paralyzed from the chest down. Alex wrote this message in her request to become a Google Glass Explorer. “I am a New Yorker, a law student, a quadriplegic. #ifihadglass I could finally capture my life on my own. I would show the world how to thrive with physical limitations in the most interesting city on the planet. With Glass, paralysis doesn’t have to be paralyzing.” Growth and M&A for Healthcare Technology companies Healthcare Technology Thought Leadership from Nelson Advisors – Market Insights, Analysis & Predictions. Visit https://www.healthcare.digital HealthTech Corporate Development - Buy Side, Sell Side, Growth & Strategy services for Founders, Owners and Investors. Email lloyd@nelsonadvisors.co.uk HealthTech M&A Newsletter from Nelson Advisors - HealthTech, Health IT, Digital Health Insights and Analysis. Subscribe Today! https://lnkd.in/e5hTp_xb HealthTech Corporate Development and M&A - Buy Side, Sell Side, Growth & Strategy services for companies in Europe, Middle East and Africa. Visit www.nelsonadvisors.co.uk #HealthTech #HealthIT #DigitalHealth #lloydgprice #NelsonAdvisors

Exec Summary: Amanda Pritchard, the NHS Chief Executive outlined the 2024/25 priorities and operational planning guidance recently, highlighting NHS England's focus for the next 12 months. "Despite the challenges we face, there are real reasons for optimism. We are already putting in place the building blocks for a better future. The £3.4 billon investment of capital in data and technology – from 2025/26 onwards – announced in the Spring Budget will allow us to roll out technology and digital services to improve access, waiting times and outcomes. Coming less than a year on from the NHS Long Term Workforce Plan, this investment has the promise to be transformational, for both patients and for our staff." NHS England's plan for Tech in 2024-2025 is centred around 5 key themes: Primary Care and GP's Virtual Wards Federated Data Platform Mental Health Digital Maturity The NHS, in common with advanced healthcare systems across the world, is facing major challenges in recovering services and meeting the growing needs of an ageing population. But this year the NHS has once again shown that it can rise to the challenge, and real improvement is possible even in the toughest of circumstances – so thank you for your continued efforts on behalf of our patients, our staff and taxpayers. Primary Care and GP's GPs are getting help to improve how patients access their services through "Modern General Practice Access." This involves: Digital tools: These tools will help patients get information, navigate the practice (like booking appointments), and ensure their needs are prioritised for the right care. Cloud phone systems: These will offer features like call-backs to avoid waiting on hold, making phone access to the GP practice smoother. 2. Virtual Wards Virtual wards will utilise tools like remote patient monitoring and rapid diagnostic tests to track patient health and make informed decisions. Increased Access and Utilisation: The goal is to get more than 80% of patients who can benefit from virtual wards to use them. Focus on Specific Conditions: Virtual wards will prioritise patients with: Frailty (age-related weakness) Acute respiratory infections (e.g., pneumonia, bronchitis) Heart failure Children and young people (CYP) Expanding Access Points: Patients will be able to access virtual wards from home ("step up" care) or directly from the Emergency Department (ED) to avoid unnecessary hospital admissions. 3. Federated Data Platform System wide engagement for use of the FDP to support: Elective recovery: Reducing waiting times for non-emergency surgeries. Care coordination: Ensuring smooth communication and collaboration between different healthcare providers involved in a patient's care. Population health: Improving overall health outcomes for entire populations by focusing on preventative measures. Vaccination: Increasing vaccination rates for important diseases. Challenge: Integrated Data Plans: Different healthcare organizations (Integrated Care Systems - ICS) need to align their data plans and investment plans to ensure the FDP system functions effectively across the network. 4. Mental Health Investment in technology to support the delivery of mental health services, with a key focus on: More personalised & joined-up: Care should be tailored to individual needs and different healthcare providers should work together seamlessly. More productive: This likely refers to improving efficiency and reducing waste within the system. More accessible: It aims to make healthcare services easier for people to reach. Faster: This means reducing waiting times for appointments, tests, and procedures. More successful: The goal is to improve overall patient outcomes. These goals align with the objectives of "Frontline Digitalisation," a program focused on: Optimising Electronic Patient Records (EPRs): This means improving the systems used to store and manage patient data electronically. Increasing digital maturity: This refers to making healthcare providers more comfortable and skilled using digital tools. 5. Digital Maturity System wide focus on improving digital maturity across all care settings: EPR Rollout: All hospitals that have completed the setup process for Electronic Patient Records (EPR) systems must be actively using them by March 2025. This ensures a consistent and standardised way of managing patient data across hospitals. Long-Term Planning:  Organizations within the NHS are required to work together to develop 10-year infrastructure strategies by July 2024. This collaborative planning will ensure long-term investment and alignment in digital infrastructure needs. Modernisation:  There's a push to continuously improve core IT systems and remove outdated legacy technology. This will likely involve upgrading systems and adopting newer, more efficient technologies. We expect integrated care boards (ICBs), trusts and primary care providers to work together to plan and deliver a balanced net system financial position in collaboration with other integrated care system (ICS) partners. We have invested in significant extra capacity over the last three years. With total NHS funding flat in real terms for 2024/25 we now need to consolidate. At the same time, we will lay the ground to improve and transform the health service for the rest of the decade, progressing the Long Term Workforce Plan (LTWP) and investing in technology. Source: https://www.england.nhs.uk/wp-content/uploads/2024/03/PRN00715-2024-to-2025-priorities-and-operational-planning-guidance-27.03.2024.pdf Growth and M&A for Healthcare Technology companies Healthcare Technology Thought Leadership from Nelson Advisors – Market Insights, Analysis & Predictions. Visit https://www.healthcare.digital HealthTech Corporate Development - Buy Side, Sell Side, Growth & Strategy services for Founders, Owners and Investors. Email lloyd@nelsonadvisors.co.uk HealthTech M&A Newsletter from Nelson Advisors - HealthTech, Health IT, Digital Health Insights and Analysis. Subscribe Today! https://lnkd.in/e5hTp_xb HealthTech Corporate Development and M&A - Buy Side, Sell Side, Growth & Strategy services for companies in Europe, Middle East and Africa. Visit www.nelsonadvisors.co.uk #HealthTech #HealthIT #DigitalHealth #lloydgprice #NelsonAdvisors

Exec Summary There is a growing body of evidence that suggests that large language models (LLMs) can be effective in a variety of healthcare applications. For example, studies have shown that LLMs can be used to: Extract insights from clinical text analysis: LLMs have been shown to be able to extract insights from unstructured clinical texts, such as electronic health records, discharge summaries, and clinical notes, with high accuracy. This can help clinicians identify trends and patterns, make more informed decisions, and improve patient care. Answer patient queries: LLMs have been shown to be able to answer patient questions about their health, medications, and treatments with high accuracy. This can help patients get the information they need quickly and easily, and it can also free up clinicians' time so they can focus on more complex tasks. Provide clinical decision support: LLMs have been shown to be able to provide clinical decision support to clinicians by helping them make more informed decisions about patient care. For example, LLMs can be used to identify potential drug interactions, suggest treatment options, and predict patient outcomes. Accelerate medical research: LLMs have been shown to be able to analyze large datasets of medical research literature to identify new insights and trends. This can help accelerate the pace of medical discovery and lead to new and better treatments for patients. However, it is important to note that LLMs are still a relatively new technology, and more research is needed to fully validate their effectiveness in healthcare settings. Additionally, it is important to use LLMs responsibly and to be aware of their potential limitations. For example, LLMs can be biased, and they can sometimes generate inaccurate or misleading information. Therefore, it is important to carefully review the output of LLMs and to consult with human experts before making any decisions based on their output. Growth and M&A for Healthcare Technology companies Healthcare Technology Thought Leadership from Nelson Advisors – Market Insights, Analysis & Predictions. Visit https://www.healthcare.digital HealthTech Corporate Development - Buy Side, Sell Side, Growth & Strategy services for Founders, Owners and Investors. Email lloyd@nelsonadvisors.co.uk HealthTech M&A Newsletter from Nelson Advisors - HealthTech, Health IT, Digital Health Insights and Analysis. Subscribe Today! https://lnkd.in/e5hTp_xb HealthTech Corporate Development and M&A - Buy Side, Sell Side, Growth & Strategy services for companies in Europe, Middle East and Africa. Visit www.nelsonadvisors.co.uk #HealthTech #HealthIT #DigitalHealth #lloydgprice #NelsonAdvisors Intro to large language models Large language models (LLMs) are a type of artificial intelligence (AI) that are trained on massive datasets of text and code. This allows them to generate text, translate languages, write different kinds of creative content, and answer your questions in an informative way. In healthcare, LLMs are being used to improve patient care in a variety of ways, including: Diagnosis and treatment: LLMs can be used to analyse patient data and identify potential health problems. They can also be used to generate treatment plans and recommend medications. Research: LLMs can be used to analyze large datasets of medical research papers. This can help researchers to identify new trends and insights. Education: LLMs can be used to create personalised learning experiences for healthcare professionals. They can also be used to create educational resources for patients and their families. Administrative tasks: LLMs can be used to automate a variety of administrative tasks in healthcare, such as scheduling appointments and generating reports. LLMs are still a relatively new technology, but they have the potential to revolutionize healthcare. By automating tasks, improving diagnosis and treatment, and supporting research, LLMs can help to make healthcare more efficient, effective, and accessible. Here are some specific examples of how LLMs are being used in healthcare: InteliHealth: InteliHealth is a US-based company that uses LLMs to create personalized health plans. Patients can use the InteliHealth website to answer questions about their health and lifestyle. The LLM will then generate a personalised plan that includes recommendations for diet, exercise, and medication. Google Health: Google Health is a personal health record (PHR) that uses LLMs to help patients manage their health. Patients can use Google Health to track their medical history, medications, and symptoms. The LLM can then generate reports and insights that can help patients to better understand their health. Viz.ai: Viz.ai is a company that uses LLMs to develop software that can help doctors to diagnose strokes and other brain injuries more quickly and accurately. Viz.ai's software uses LLMs to analyse medical images, such as CT scans and MRI scans, and to identify potential abnormalities. GNS Healthcare: GNS Healthcare is a company that uses LLMs to develop software that can help clinicians to make better treatment decisions. GNS Healthcare's software uses LLMs to analyse patient data, such as medical records, laboratory results, and imaging data, to identify the best course of treatment for each individual patient. Health Catalyst: Health Catalyst offers a variety of LLM-powered solutions for healthcare organizations. For example, Health Catalyst's LLM-powered platform can be used to identify patients who are at high risk for certain conditions, such as heart disease and diabetes. This information can then be used to develop targeted prevention and intervention programs These are just a few examples of how LLMs are being used in healthcare. As LLMs continue to develop, we can expect to see even more innovative and effective applications of this technology in the years to come. Advantages of large language models in healthcare AI Here are some of the advantages of using LLMs in healthcare: Improved diagnosis and treatment: LLMs can be used to analyse patient data and identify potential health problems. They can also be used to generate treatment plans and recommend medications. This can help to improve the accuracy and efficiency of healthcare delivery. Support for research: LLMs can be used to analyze large datasets of medical research papers. This can help researchers to identify new trends and insights that can lead to new treatments and cures. Personalised learning experiences: LLMs can be used to create personalized learning experiences for healthcare professionals. This can help them to stay up-to-date on the latest medical knowledge and best practices. Automated administrative tasks: LLMs can be used to automate a variety of administrative tasks in healthcare, such as scheduling appointments and generating reports. This can free up healthcare professionals to focus on providing care to patients. Overall, LLMs have the potential to revolutionize healthcare by making it more efficient, effective, and accessible. As LLMs continue to develop, we can expect to see even more innovative and effective applications of this technology in the years to come. Disadvantages of large language models in healthcare AI LLMs are still a relatively new technology, but they have the potential to revolutionise healthcare. By automating tasks, improving diagnosis and treatment, and supporting research, LLMs can help to make healthcare more efficient, effective, and accessible. However, there are also some potential disadvantages to using LLMs in healthcare, including: Bias: LLMs are trained on massive datasets of text and code, which can introduce bias into the model. This bias can lead to inaccurate or unfair results, especially when the model is used to make decisions about patient care. Accuracy: LLMs are still under development, and their accuracy can vary depending on the task at hand. In some cases, LLMs may not be accurate enough to be used in clinical settings. Interpretability: LLMs are complex models, and it can be difficult to understand how they make decisions. This can make it difficult to trust the results of LLMs, especially in critical situations. Security: LLMs can be vulnerable to security attacks, which could allow attackers to manipulate the model or steal sensitive data. Overall, LLMs have the potential to revolutionise healthcare, but it is important to be aware of the potential risks and limitations of this technology. As LLMs continue to develop, it is important to ensure that they are used in a safe and responsible manner. Final Thoughts Large language models (LLMs) are a subset of deep learning. Deep learning is a type of machine learning that uses artificial neural networks to learn from data. Neural networks are inspired by the structure and function of the human brain, and they are made up of layers of interconnected nodes. Each node performs a simple mathematical operation, and the nodes are connected in such a way that the output of one node becomes the input to the next node. LLMs are a type of deep learning model that is specifically designed to learn and process language. LLMs are trained on massive datasets of text and code, and they learn to identify patterns and relationships in language. This allows LLMs to perform a variety of tasks, such as generating text, translating languages, and answering questions in a comprehensive and informative way. Some of the most popular LLMs include GPT-3, LaMDA, and PaLM. These models have been shown to be capable of performing a wide range of tasks, including: Generating text that is indistinguishable from human-written text Translating languages with high accuracy Answering questions in a comprehensive and informative way, even when they are open ended, challenging, or strange Writing different kinds of creative text formats of text content, like poems, code, scripts, musical pieces, email, letters, etc. LLMs are still under development, but they have the potential to revolutionise the way we interact with computers and the world around us. Growth and M&A for Healthcare Technology companies Healthcare Technology Thought Leadership from Nelson Advisors – Market Insights, Analysis & Predictions. Visit https://www.healthcare.digital HealthTech Corporate Development - Buy Side, Sell Side, Growth & Strategy services for Founders, Owners and Investors. Email lloyd@nelsonadvisors.co.uk HealthTech M&A Newsletter from Nelson Advisors - HealthTech, Health IT, Digital Health Insights and Analysis. Subscribe Today! https://lnkd.in/e5hTp_xb HealthTech Corporate Development and M&A - Buy Side, Sell Side, Growth & Strategy services for companies in Europe, Middle East and Africa. Visit www.nelsonadvisors.co.uk #HealthTech #HealthIT #DigitalHealth #lloydgprice #NelsonAdvisors

Exec Summary: The convergence of healthcare and technology (HealthTech) has created a booming digital health industry. But technology alone isn't enough. Behaviour science is emerging as a powerful force in this field, with the potential to revolutionise how we approach health and wellness. Why is Behaviour Science Important? Understanding the "Why": Traditional medicine often focuses on the "what" (disease diagnosis and treatment). Behavioral science delves into the "why" behind health behaviors. It helps us understand why people make certain choices and how to nudge them towards healthier habits. Boosting Engagement: Many digital health tools struggle with user engagement. Behavioral science principles like gamification and reward systems can make these tools more engaging and motivating, leading to better long-term results. Personalized Interventions: A one-size-fits-all approach rarely works in healthcare. Behavioral science helps create personalized interventions that consider individual needs, preferences, and contexts. Imagine a fitness app that suggests workouts based on your personality type, or a chronic disease management program that adapts to your daily routine. The Future of Behaviour Science in HealthTech Just-in-Time Adaptive Interventions (JITAIs): Imagine receiving a craving suppressant notification right before you walk past a fast-food joint, or a nudge to meditate when your smartwatch detects rising stress. JITAIs deliver the right support at the right moment, maximising impact. Micro-randomized Control Trials (MRTs): These research studies help fine-tune JITAIs by testing different intervention components in real-time. Like a scientist testing pizza combinations, MRTs identify the most effective elements for specific situations. Hyper-personalization: The future lies in interventions tailored to individual needs and preferences. Imagine AI-powered health tools that analyse user data and recommend personalised strategies in real-time. Focus on preventative care: Behavioral science can revolutionize preventative care by designing apps that encourage healthy habits. Sleep trackers that nudge you towards a consistent sleep schedule are a prime example. Challenges and Considerations Digital Equity: Not everyone has access to smartphones or reliable internet. It's crucial to bridge the digital divide to ensure everyone benefits from these advancements. Data Privacy: As healthcare data becomes more integrated with digital tools, robust privacy measures are essential to build trust with users. Overall, the future of behavior science in HealthTech and digital health is about creating a user-centric experience that empowers individuals to take charge of their health and well-being. By understanding and influencing behavior, we can create a healthier future for everyone. Growth and M&A for Healthcare Technology companies Healthcare Technology Thought Leadership from Nelson Advisors – Market Insights, Analysis & Predictions. Visit https://www.healthcare.digital HealthTech Corporate Development - Buy Side, Sell Side, Growth & Strategy services for Founders, Owners and Investors. Email lloyd@nelsonadvisors.co.uk HealthTech M&A Newsletter from Nelson Advisors - HealthTech, Health IT, Digital Health Insights and Analysis. Subscribe Today! https://lnkd.in/e5hTp_xb HealthTech Corporate Development and M&A - Buy Side, Sell Side, Growth & Strategy services for companies in Europe, Middle East and Africa. Visit www.nelsonadvisors.co.uk #HealthTech #HealthIT #DigitalHealth #lloydgprice #NelsonAdvisors Future of Behavioural Science in HealthTech and Digital Health The future of behavioural science in HealthTech and digital health is bright, with the potential to revolutionise how we approach healthcare. Here are some exciting trends to look for: 1. Hyper-personalized interventions:  Behavioral science will help create interventions tailored to individual needs and preferences. Imagine a fitness app that uses nudges based on your personality type, or a chronic disease management program that adapts to your daily routine. 2. Gamification and motivation:  Digital health tools will leverage behavioral science principles like gamification and reward systems to boost user engagement. Think earning points for healthy habits or competing with friends in a step challenge. 3. AI-powered behavior change:  Artificial intelligence (AI) will personalize interventions further by analyzing user data and recommending strategies in real-time. Imagine an app that prompts you to meditate during moments of peak stress, identified through physiological data. 4. Addressing adherence challenges:  Behavioral science will play a crucial role in tackling medication adherence and treatment plan completion. We might see digital reminders that consider forgetfulness patterns or motivational messages tailored to address specific anxieties. 5. Focus on preventative care:  The future lies in preventing illness rather than just treating it. Behavioral science will be instrumental in designing apps that encourage healthy habits, like sleep trackers that nudge you towards a consistent sleep schedule. Challenges to consider: Digital equity: It's crucial to ensure everyone has access to these advancements. Behavioral science can help design solutions that bridge the digital divide. Data privacy concerns: As healthcare data becomes more integrated with digital tools, robust privacy measures will be essential to build trust with users. Overall, the future of behavioral science in HealthTech and digital health is about creating a user-centric experience that empowers individuals to take charge of their health and well-being. By understanding and influencing behaviour, we can create a healthier future for everyone. New and Emerging Methodologies, Techniques and Frameworks The field of behavioural science in HealthTech is constantly evolving, with new methodologies, techniques, and frameworks emerging to address the complexities of human behaviour and improve health outcomes. Here are some exciting trends to watch: Methodologies: Ecological Momentary Assessment (EMA) with Experience Sampling: We discussed EMA earlier, but it's worth noting its growing sophistication. EMA combined with experience sampling involves prompting users to report on their experiences (cravings, emotions) and the surrounding context (location, social setting) in real-time using smartphones. This rich data helps understand behaviour within the natural environment. Passive Data Collection: Leveraging data from wearables (heart rate, sleep patterns) and smartphone usage (location, app activity) can provide valuable insights without requiring explicit user input. This unobtrusive approach minimises bias and reveals behaviour patterns users might not even be aware of. N-of-1 Trials: These personalized trials involve a single participant trying different intervention variations over time. This allows for highly individualised insights on what works best for a specific person, paving the way for ultra-personalised health programs. Techniques: Habit Formation Techniques: Techniques like habit stacking (pairing a new habit with an existing one) and cue identification (recognising triggers for unhealthy behaviours) can be embedded in digital tools to help users build positive routines and break negative ones. Loss Aversion Framing: People are more motivated to avoid losses than acquire gains. Framing health messages around avoiding negative consequences (e.g., "Quitting smoking reduces your risk of heart disease by 50%") can be more impactful than simply highlighting the benefits of quitting. Social Influence and Gamification: Leveraging the power of social support and healthy competition can boost motivation. Imagine earning badges for completing healthy tasks in a fitness app or seeing friends' progress on a shared health goal. Frameworks: The COM-B Model: This framework identifies three key factors influencing behavior: Capability (skills and knowledge), Opportunity (environmental factors), and Motivation (psychological drivers). JITAIs can be designed to address each factor for optimal impact. The Fogg Behavior Model: This model focuses on three elements necessary for behavior change: Motivation, Ability, and Prompt. Digital health tools can be designed to ensure these elements are present for users to engage in desired behaviours. The BHIRT Framework: This framework stands for Behavior, Health, Intervention, and Technology. It guides researchers in developing and evaluating digital health interventions that consider the specific behaviour, health target, intervention design, and technological platform. These are just a few examples, and the field is constantly evolving. As technology advances and our understanding of human behaviour deepens, we can expect even more innovative methodologies, techniques, and frameworks to emerge, shaping the future of HealthTech and empowering individuals to lead healthier lives. Ecological Momentary Assessments (EMAs) An ecological momentary assessment (EMA), also sometimes referred to as experience sampling or daily diary method, is a research method used in psychology and other social sciences to collect data on people's experiences in real-time, as they happen in their natural environments. Why use EMA? Traditional methods for collecting data on people's experiences, such as surveys and interviews, rely on people's memories of past events. This can be problematic because our memories are often inaccurate, biased by our current mood or perspective. EMAs aim to address this problem by collecting data in the moment, when the experience is fresh in the person's mind. How does EMA work? EMA studies typically involve participants carrying a small electronic device, such as a smartphone, which prompts them to answer questions about their experiences at random intervals throughout the day. The questions can be about a variety of topics, such as the participant's mood, thoughts, behaviors, and the context in which they are occurring. Benefits of EMA Reduced recall bias: By collecting data in real-time, EMAs can help to reduce the bias that can occur when people are asked to recall past events. Ecological validity: Because data is collected in participants' natural environments, EMAs can provide a more accurate picture of how people think, feel, and behave in their everyday lives. Increased temporal resolution: EMAs allow researchers to collect data on a more frequent basis than is possible with traditional methods, such as surveys and interviews. This can be useful for studying how experiences change over time. Examples of EMA research EMA studies have been used to investigate a wide range of topics, including: Mental health: EMAs have been used to study the daily experiences of people with depression, anxiety, and other mental health conditions. Substance abuse: EMAs have been used to track people's cravings for drugs and alcohol, and to identify the triggers that lead to substance use. Stress: EMAs have been used to study how people cope with stress in their everyday lives. Pain management: EMAs have been used to track people's pain levels and to identify the factors that influence pain perception. The future of EMA EMA is a rapidly growing field of research. As technology advances, EMA studies are becoming more sophisticated and are being used to investigate a wider range of topics. EMAs have the potential to revolutionise the way we study human behaviour. 2. Just in time adaptive interventions (JITAIs) Just-in-time adaptive interventions (JITAIs) are a promising approach in the realm of digital health and behavioural science. They essentially provide right-time, right-place support to nudge people towards positive behaviours. Here's a breakdown of JITAIs: Right-time: Imagine receiving a craving buster notification exactly when you're walking past a fast-food joint, or an encouragement to meditate when your smartwatch detects rising stress levels. JITAIs deliver interventions when they're most likely to be effective. Right-place: Location awareness can further personalize JITAIs. An app prompting you to do some stretches when you arrive at your work desk can help prevent repetitive strain injuries. Key features of JITAIs: Real-time support: JITAIs leverage technology like smartphones and wearables to collect data and deliver interventions in real-time. Adaptive: They consider an individual's context and needs, tailoring the intervention accordingly. System-triggered: JITAIs are automated, prompting support based on pre-defined rules or algorithms. Benefits of JITAIs: Increased effectiveness: By providing support at the opportune moment, JITAIs have the potential to be more impactful than generic interventions. Reduced burden: JITAIs can be less intrusive than traditional methods, offering targeted support instead of overwhelming users. Improved adherence: Real-time nudges can help people stay on track with their goals and treatment plans. Applications of JITAIs: Health behaviour change: Promoting physical activity, healthy eating, medication adherence, smoking cessation, etc. Mental health interventions: Delivering coping strategies for anxiety or stress in the moment. Chronic disease management: Providing reminders or adjustments to medication plans based on real-time health data. JITAIs are still evolving, but they hold immense potential to personalise and enhance interventions across various healthcare and wellness domains. 3. Micro-randomised control trials (MRT's) A micro-randomised control trial (MRT) is a research design specifically used to optimise JITAIs (just-in-time adaptive interventions). It essentially tests different components of a JITAI to see which ones work best and when. Here's how MRTs work: Participants: People who would benefit from a JITAI (e.g., someone trying to quit smoking or manage stress). Multiple decision points: Throughout the study, participants encounter situations where the JITAI could be triggered (e.g., a craving for a cigarette, feeling overwhelmed). Randomization: At each decision point, participants are randomly assigned to receive a specific version of the JITAI or no intervention at all (control group). This allows researchers to compare the effectiveness of different intervention options. Data collection: The MRT collects data on various aspects, including what intervention was delivered, the participant's response, and the desired outcome (e.g., resisting a craving, using a coping strategy). Benefits of MRTs: Optimize JITAIs: By testing different intervention components, researchers can identify the most effective elements for a specific context. Real-world simulation: MRTs happen in real-time, mimicking how JITAIs would function in practice. Evaluate tailoring: They allow researchers to assess if tailoring interventions based on individual data points leads to better outcomes. Here's an analogy: Imagine personalizing a pizza recipe. An MRT would be like trying out different cheese combinations, crust types, and veggie toppings at various points during the cooking process to see which combinations create the tastiest pizza. Overall, MRTs are a valuable tool for developing and refining JITAIs, ultimately leading to more effective digital health interventions. Growth and M&A for Healthcare Technology companies Healthcare Technology Thought Leadership from Nelson Advisors – Market Insights, Analysis & Predictions. Visit https://www.healthcare.digital HealthTech Corporate Development - Buy Side, Sell Side, Growth & Strategy services for Founders, Owners and Investors. Email lloyd@nelsonadvisors.co.uk HealthTech M&A Newsletter from Nelson Advisors - HealthTech, Health IT, Digital Health Insights and Analysis. Subscribe Today! https://lnkd.in/e5hTp_xb HealthTech Corporate Development and M&A - Buy Side, Sell Side, Growth & Strategy services for companies in Europe, Middle East and Africa. Visit www.nelsonadvisors.co.uk #HealthTech #HealthIT #DigitalHealth #lloydgprice #NelsonAdvisors

Exec Summary: Nelson Advisors partner Lloyd Price co-authored the Oxford University Venture Capital Network: Insights into Digital Health Report with Ava Chan - DPhil candidate in Biology, Ellena O’Keeffe -  MSc in Applied Cancer Science, Sili (Bobby) Qiu - DPhil candidate in Organic Chemistry, Adriana Mordente - DPhil candidate in Biology, Aneshka Moudry - MChem Chemistry. About Oxford University Venture Capital Network (OXVC) The Oxford University Venture Capital Network (OXVC) is a network of start-up founders, investors, and entrepreneurial Oxford students, supported by Oxford Science Enterprises and Presidio Ventures. For many students and founders, venture capital is a mysterious, complex, and inaccessible industry. We’re here to  demystify  it. VCs shape the future of the world through their investments, changing how we socialise, bank, travel, access healthcare, and beyond. However, VC is one of the least diverse industries. Women constitute only 30% of VC personnel in the UK and ethnic diversity is low. We want to  change  that. We take raw student talent, ambition, and vision and work directly with VC funds to provide a grounding in the theoretical and practical aspects of funding innovative ideas through to profitable outcomes. We nurture future innovators. Insights into Digital Health Report Below is an executive summary of the Oxford University Venture Capital Network: Insights into Digital Health Report, the full report will be published in due course. Digital Health definition We define Digital Health as the development and use of digital technologies making their way into products and companies for the first time to improve health outcomes. Market , Innovation & Funding Landscape The largest market for digital health is in North America, whereas the fastest growing market is in the Asia-Pacific region.  The biggest innovation hotspots constitute London, followed by Oxford, Cambridge and Southampton. Technology and Segment Deep Dives We provide in-depth market analysis into the digital health industry segmented into Data Collection & IT, Diagnostics, Disease management and Digital therapeutics.  Data Collection and IT As healthcare systems shift towards outcomes-based models, the demand for integrated data platforms that support personalised patient care, real-time data analytics, and efficient healthcare delivery is surging.  New entrants in this space should focus on developing innovative, scalable health tech solutions that align with Value-Based Care principles, ensuring regulatory compliance and addressing unmet needs in patient care and data management.  Market strategies should emphasize collaborating with existing healthcare players, demonstrate clear clinical and cost-efficiency outcomes and ensure seamless integration with existing healthcare systems. B2B segment to dominate the market due to increasing strategic collaborations and the building of verticals. Diagnostics (Point of Care Technology) The increasing prevalence of chronic diseases and an ageing population underscore the importance of Point of Care Technology (POCT) implementation into primary care clinics. Molecular diagnostics technology is the fastest-growing segment within POCT. POCT is a competitive market and could potentially limit product innovation and market expansion.  The primary users and beneficiaries of POCT over the next five years will be doctors in hospitals and clinics, who demand a high volume of devices and consumables. Disease Management The CKD management market is large and growing, driven by technological innovation and increasing demand for advanced treatments. Regulatory approval in key markets like the US and UK is crucial for the adoption of new technologies. The field faces challenges such as treatment costs, access to care, and the complexity of disease management. Startups and investors active in this space have significant opportunities for innovation and growth, with the potential for lucrative exits through acquisitions or IPOs. This landscape scan provides a foundational understanding of the venture capital dynamics in the CKD management sector, highlighting the opportunities for innovation and investment in this critical area of healthcare. Digital Therapeutics (DTx) DTx has great potential, and it has a growing market. At the same time, the market is getting crowded and has a few regulatory hurdles.  DTx can extend care to a wider group of people compared to traditional medicine.  The main challenges include the lack of regulatory and cybersecurity infrastructure for this emerging field, and limited clinical adoption due to lack of awareness or education.  Reimbursement model hinders DTx clinical translation as patients become hesitant to try out advanced technologies.  DTx startups' go-to-market strategies need to address a broad range of stakeholders in the DTx ecosystem to gain successful market entry, and clinical adoption can be improved through digital health education.  It is foreseeable that DTx will be integrated into emerging technologies such as smart implants and have greater emphasis on preventive care . Updates from the Oxford University Venture Capital Network Receive the latest and greatest Oxford and worldwide entrepreneurial news and events straight to your inbox. - https://mailchi.mp/295f16a3929d/signup

In a new series of Digital Health Intelligence Market Analysis, HealthTech Founder and M&A Advisor Lloyd Price examines a range of high potential market segments in the UK, including: 1. Virtual Care – From Hype to Reality 2. Patient Engagement Platforms – Rebuilding Trust in the NHS 3. Population Health – from Reactive Care to Proactive Prevention 4. Digital Therapeutics – looking forward to a year of growth 5. AI in Clinical Imaging – shaping the future of healthcare 6. Electronic Bed and Capacity Management Systems - crucial support for an NHS under pressure 7. Shared Care Records - a time of transition and expansion Digital Health Intelligence Market Analysis - from identifying high value market segments to sales prospecting, Intelligence supports multiple teams with essential insights and reliable, granular-level data on NHS acute and mental health trusts, central bodies, STPs, ICSs and commissioning organisations. Digital Health Intelligence is the 'Trusted Authority on Digital Health' in the UK - Subscribe Today! https://lnkd.in/e8ZVAdGT 1. DHI Market Analysis: Virtual Care – From Hype to Reality In the first of a new series of analyses for Digital Health Intelligence subscribers, Lloyd Price examines the virtual care market. Virtual care holds potential in healthcare delivery, blending innovation with tradition. However, beneath the surface lies complexity. NHS frontline staff, navigating post-COVID challenges, perceive virtual wards as additional digital tasks, amid staffing shortages and mounting hurdles. 2. DHI Market Analysis: Patient Engagement Platforms – Rebuilding Trust in the NHS Patient engagement platforms are gaining momentum with NHS England’s backing. They’re central to the ‘Digital Front Door’ strategy, focusing on patient-facing services, enhancing secondary care, and reducing the strain on frontline services. These platforms address the pandemic-induced disconnect between patients and the NHS. 3. DHI Market Analysis: Population Health – from Reactive Care to Proactive Prevention This report offers a comprehensive overview of the evolving landscape of population health management and the challenges and opportunities it presents to the NHS. It underscores the importance of proactive approaches to healthcare and the critical role that data and technology will play in shaping the future of healthcare in the UK. 4. DHI Market Analysis: Digital Therapeutics – looking forward to a year of growth The Digital Health Intelligence (DHI) Market Analysis on Digital Therapeutics highlights the transformative impact of evidence-based interventions delivered through devices. In the past year, there has been a significant surge in the adoption of digital therapeutics, especially within the NHS, addressing various healthcare challenges. 5. AI in Clinical Imaging – shaping the future of healthcare Our analysis of AI in Clinical Imaging reveals a significant NHS commitment to leveraging artificial intelligence for improved patient care. The NHS AI Lab, regional networks, and funding initiatives showcase strategic investments in cutting-edge technology. Real-world examples from leading healthcare providers highlight AI’s tangible benefits, while acknowledging challenges such as data quality and ethical considerations. Looking ahead, the report anticipates AI’s continued impact on disease detection and patient outcomes, underscoring its promising role in reshaping clinical imaging practices. 6. Electronic Bed and Capacity Management Systems - crucial support for an NHS under pressure The Digital Health Intelligence (DHI) Market Analysis delves into the realm of Electronic Bed and Capacity Management Systems (eBCMS), shedding light on their key role in supporting an NHS under pressure. Faced with challenges such as strained resources, the impact of the Covid-19 pandemic, and prolonged waiting times in A&E, the NHS has increasingly embraced eBCMS to enhance patient flow, reduce waiting times, and optimise bed utilisation. This report explores the trajectory of eBCMS adoption, available funding, notable examples, leading suppliers, and the future landscape 7. Shared Care Records - a time of transition and expansion This Market Analysis of Shared Care Records (SCRs) reveals a dynamic landscape within the NHS marked by both progress and persistent challenges. While many regions have effectively implemented SCRs, barriers such as interoperability and a focus on planned care hinder widespread adoption. Funding for the Connecting Care Records (ConCR) programme, vital for sustainability beyond 2025, remains uncertain, although avenues for support from agencies like Innovate UK exist. Highlighted examples of successful SCR implementations include the Yorkshire and Humber Care Record, Great North Care Record, and One London initiative. Leading suppliers like Graphnet, Oracle Health, Orion Health, and InterSystems offer sophisticated solutions, enhancing data sharing and patient care coordination. Future of shared care records In the short term, unlocking patient access to shared care records is undoubtedly one of the main areas of focus in the future. The benefits of functionality such as'delegated access' - enabling partners, parents, carers, legal guardians and nursing home staff to view information such an individual's test results or treatment plan - are considerable, potentially saving hours of time and reducing stress for individuals. The importance of enabling patients and their support teams to effectively share and see the same information as clinicians should not be underestimated: seeing the complete medical picture should lead to better care coordination and outcomes. In the mid to long term, ensuring all data in shared care record platforms follows recognised data standards will be a key building block for unlocking the potential of AI. AI algorithms could predict future health outcomes based on historical data held in SCRs, allowing healthcare professionals to take proactive steps and personalise treatment plans. AI could also analyse vast amounts of medical data from SCRs, uncovering patterns and potential health risks for individual patients or entire populations. This could lead to early diagnoses and preventative measures. One year from now The next 12 months promise significant advancements in SCRs across the NHS with increased standardisation, wider adoption and improved functionalities leading to better communication and collaboration among healthcare providers, benefiting patient care. We should see the completion of the Connecting Care Records (ConCR) programme and associated benefits, building more confidence in the system to increase training for staff on SCRs. We can also expect more business cases to expand usage from primary care and acute care into urgent care, community care and mental health trusts. Digital Health Intelligence Digital Health Intelligence is the 'Trusted Authority on Health IT, HealthTech and Digital Health' in the UK - Subscribe Today! https://lnkd.in/e8ZVAdGT Digital Health Intelligence: Digital Health provides independent business, policy and technology news, research and events focused on developments in health IT in the NHS and UK health. Our coverage is focused, original and authoritative. Over 20,000 readers subscribe to Digital Health’s newsletters. Digital Health News provides daily news and analysis on the UK health IT sector, spanning NHS IT infrastructure, enterprise and clinical systems such as EPR (electronic patient records) to emerging and disruptive technologies, including AI, apps and wearables. Digital Health Intelligence is our market intelligence data business providing the most detailed database available on the current systems, technology and infrastructure installed at every NHS trust in the UK, together with future purchasing intentions and market trends analysis. The subscription-based service enables suppliers to understand and target market opportunities. Digital Health Intelligence is the 'Trusted Authority on Health IT, HealthTech and Digital Health' in the UK - Subscribe Today! https://lnkd.in/e8ZVAdGT

Exec Summary: HealthTech Founder and M&A Advisor Lloyd Price will judge the HealthInvestor Awards 2024, with the Awards evening and presentations taking place on the 5th June 2024 at the Grosvenor House Hotel in London. The Awards are hosted by Nexus Media Group, a leading B2B publishing and events company for the health, social care, seniors housing, education, early years and property sectors. Nexus Media Group is a publishing and events company, which focuses on the health, education, early-years and property sectors. Our range of established media titles and sector-leading events provide market intelligence and business connections, underpinned by a long-standing commitment to editorial excellence. Established in 2004, our London-based team of journalists and sector experts provide insight and introductions to complex marketplaces. 2024 Category Finalists Bank/Lender of the Year - Finalists AIB GB Ares Management Barclays Cynergy Bank Leumi UK NatWest Group OakNorth Puma Property Finance Shawbrook Bank Silbury Speciality Finance ThinCats Virgin Money Consultants of the Year – Strategic - Finalists AlixPartners Candesic CBRE Carnall Farrar Connell Consulting Envision Knight Frank Mansfield Advisors Teneo Business Consulting Consultants of the Year – Transactional - Finalists AlixPartners Candesic Connell Consulting Knight Frank Mansfield Advisors PMSI Strategy Consultants of the Year - PR - Finalists Arc Seven Communications PLMR Group Prosperwell Silver Buck Corporate Financier of the Year - Finalists Alantra Christie Finance Clearwater International Cooper Parry Deloitte Eclipse Corporate Finance Grant Thornton Hazlewoods KPMG Legal Advisors of the Year – Private - Finalists Addleshaw Goddard BCLP Bevan Brittan Browne Jacobson DAC Beachcroft Freeths Hill Dickinson Lester Aldridge Mills & Reeve Pinsent Masons RWK Goodman Travers Smith Legal Advisors of the Year – Public - Finalists Bevan Brittan Browne Jacobson Burges Salmon DAC Beachcroft Hill Dickinson Kennedys Law Mills & Reeve Pinsent Masons Weightmans Legal Advisors of the Year – Transactional - Finalists Acuity Law Addleshaw Goddard Bevan Brittan Browne Jacobson Carter Bond Charles Russell Speechlys HCR Law Hill Dickinson Lester Aldridge Mills & Reeve Pinsent Masons RWK Goodman Executive Search Firm of the Year - Finalists Compass Recruitment Solutions (CSR) Odgers Berndtson / Berwick Partners Finegreen Recruitment Firm of the Year - Finalists Menlo Park Linq Compass Recruitment Solutions (CSR) Investment - Private Equity Investor of the Year - Finalists Apposite Capital Downing GHO Capital LDC MTIP Patron Capital Previous HealthInvestor Awards Judges - 2023 and 2022 Growth and M&A for Healthcare Technology companies Healthcare Technology Thought Leadership from Nelson Advisors – Market Insights, Analysis & Predictions. Visit https://www.healthcare.digital HealthTech Corporate Development - Buy Side, Sell Side, Growth & Strategy services for Founders, Owners and Investors. Email lloyd@nelsonadvisors.co.uk HealthTech M&A Newsletter from Nelson Advisors - HealthTech, Health IT, Digital Health Insights and Analysis. Subscribe Today! https://lnkd.in/e5hTp_xb HealthTech Corporate Development and M&A - Buy Side, Sell Side, Growth & Strategy services for companies in Europe, Middle East and Africa. Visit www.nelsonadvisors.co.uk #HealthTech #HealthIT #DigitalHealth #lloydgprice #NelsonAdvisors

Exec Summary: Personal health large language models (LLMs) are an exciting new area in healthcare that uses AI to provide users with personalised guidance and support. Here's a breakdown of how they work and their potential: What exactly are Personal health LLMs? LLMs are essentially AI models trained on massive amounts of health data and text. This allows them to understand and respond to your questions and concerns in a way that's relevant to you. What can Personal health LLMs do? Health Coaching: Imagine a virtual coach that can analyze your health data (with your permission, of course) and provide personalized recommendations for diet, exercise, and overall well-being. Health Information: LLMs can translate complex medical jargon into easy-to-understand language and answer your questions about specific conditions or treatments. Improved Communication: LLMs can help bridge the gap between patients and doctors by facilitating communication and streamlining administrative tasks. Benefits of Personal health LLMs: Better Understanding: LLMs can empower patients to take charge of their health by improving their understanding of their conditions and treatment options. Increased Engagement: A personalized approach can motivate users to stay on track with their health goals. Clinician Support: LLMs can free up doctors' time by handling routine tasks and providing patients with initial guidance. Early days of Personal health LLMs: Early Days: Personal health LLMs are still under development, and their capabilities are constantly evolving. Not a Replacement: LLMs should not be seen as a replacement for qualified medical professionals. Data Privacy: Security and privacy of personal health data is paramount. Overall, personal health LLMs have the potential to revolutionize healthcare by providing accessible, informative, and personalized support to users. Growth and M&A for Healthcare Technology companies Healthcare Technology Thought Leadership from Nelson Advisors – Market Insights, Analysis & Predictions. Visit https://www.healthcare.digital HealthTech Corporate Development - Buy Side, Sell Side, Growth & Strategy services for Founders, Owners and Investors. Email lloyd@nelsonadvisors.co.uk HealthTech M&A Newsletter from Nelson Advisors - HealthTech, Health IT, Digital Health Insights and Analysis. Subscribe Today! https://lnkd.in/e5hTp_xb HealthTech Corporate Development and M&A - Buy Side, Sell Side, Growth & Strategy services for companies in Europe, Middle East and Africa. Visit www.nelsonadvisors.co.uk #HealthTech #HealthIT #DigitalHealth #lloydgprice #NelsonAdvisors FitBit and Google Research: 'Fitbit and Google Research are working together to build a Personal Health Large Language Model that can power personalized health and wellness features in the Fitbit mobile app, helping people get even more insights and recommendations from the data from their Fitbit and Pixel devices. This model is being fine-tuned to deliver personalized coaching capabilities, like actionable messages and guidance, that can be individualized based on personal health and fitness goals. For example, this model may be able to analyze variations in your sleep patterns and sleep quality, and then suggest recommendations on how you might change the intensity of your workout based on those insights. This model is being built on Gemini models and fine-tuned on a de-identified, diverse set of health signals from high-quality research case studies. The studies are being collected and validated in partnership with accredited coaches and wellness experts, enabling the model to exhibit profound reasoning capabilities on physiological and behavioural data. For example, we’re testing performance using sleep medicine certification exam-like practice tests, and are already seeing that our model currently performs well. We'll continue to iterate and learn as we build this new Personal Health Large Language Model, and will share more research soon.' Source: https://blog.google/technology/health/google-generative-ai-healthcare/ InteliHealth's personalised health plan InteliHealth is a US-based company that uses LLMs to create personalised health plans. Patients can use the InteliHealth website to answer questions about their health and lifestyle. The LLM will then generate a personalised plan that includes recommendations for diet, exercise, and medication. What InteliHealth offers: Interactive Platform: You interact with InteliHealth through their website or app. Health Assessment: You answer a series of questions about your health history, lifestyle habits (diet, exercise, sleep), and any current health concerns. LLM Analysis: InteliHealth's LLM analyzes your responses, considering vast amounts of healthcare data and research. Personalized Plan: Based on the analysis, the LLM generates a personalized health plan with recommendations for: Diet: The plan might suggest specific foods or dietary patterns based on your needs and goals. Exercise: You might receive recommendations for types and duration of exercise routines. Medication (with disclaimers): In some cases, the plan might suggest over-the-counter medications but with a strong emphasis on consulting a doctor for confirmation and prescriptions. Important Considerations: Early Stage: InteliHealth's LLM technology is still under development, so its recommendations should be viewed as a starting point, not a definitive diagnosis or treatment plan. Doctor Consultation: InteliHealth emphasizes the importance of consulting a doctor before making any major changes to your diet, exercise routine, or medication use. The LLM cannot replace a qualified medical professional. Data Privacy: When using InteliHealth, make sure you understand their data privacy practices to ensure your health information is secure. Overall, InteliHealth's LLM-based personalized health plans offer a convenient and potentially helpful way to take charge of your well-being. However, it's crucial to remember it's a tool to be used in conjunction with consulting a doctor for personalised medical advice. Future of personal health LLMs The future of personal health LLMs (large language models) is brimming with exciting possibilities that could transform how we manage our health. Here's a glimpse into what the coming years might hold: Advanced Capabilities: Precision Medicine: LLMs could be fine-tuned to analyze an individual's unique genetic makeup, health history, and lifestyle data to provide hyper-personalized recommendations for disease prevention, treatment, and overall well-being. Mental Health Support: LLMs could offer more sophisticated mental health chatbots trained to recognize and address symptoms of anxiety, depression, and other mental health conditions. They could provide emotional support, guide users to relevant resources, and even flag potential situations requiring professional intervention. Proactive Health Management: Imagine an LLM constantly monitoring your health data from wearables and other sources, identifying potential health risks early on and suggesting preventive measures. Integration and Collaboration: Seamless Healthcare Ecosystem: LLMs could seamlessly connect with electronic health records, wearables, and other healthcare devices, creating a unified platform for managing your health data and receiving personalized insights. Enhanced Doctor-Patient Communication: LLMs could act as intelligent assistants for doctors, summarizing patient data, translating medical jargon for patients, and facilitating more informed conversations. Addressing Challenges: Data Privacy and Security: Robust security measures will be crucial to ensure the privacy of sensitive health data used by LLMs. Algorithmic Bias: Mitigating bias in the data used to train LLMs is essential to prevent unfair or inaccurate recommendations. Accessibility and Equity: Efforts must be made to ensure everyone has access to personal health LLMs, regardless of socioeconomic background or technical expertise. Overall, the future of personal health LLMs is promising. As these AI models become more sophisticated and integrated into healthcare systems, they have the potential to empower individuals, improve preventative care, and revolutionise the way we approach our health. Growth and M&A for Healthcare Technology companies Healthcare Technology Thought Leadership from Nelson Advisors – Market Insights, Analysis & Predictions. Visit https://www.healthcare.digital HealthTech Corporate Development - Buy Side, Sell Side, Growth & Strategy services for Founders, Owners and Investors. Email lloyd@nelsonadvisors.co.uk HealthTech M&A Newsletter from Nelson Advisors - HealthTech, Health IT, Digital Health Insights and Analysis. Subscribe Today! https://lnkd.in/e5hTp_xb HealthTech Corporate Development and M&A - Buy Side, Sell Side, Growth & Strategy services for companies in Europe, Middle East and Africa. Visit www.nelsonadvisors.co.uk #HealthTech #HealthIT #DigitalHealth #lloydgprice #NelsonAdvisors